Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer

Digestion

Volumn 88, Issue 3, 2013, Pages 172-181

  Göke, Friederike ^a   Göke, Antonia ^a   Von Mässenhausen, Anne ^a   Franzen, Alina ^a   Sharma, Rakesh ^a   Kirsten, Robert ^a   Böhm, Diana ^a   Kristiansen, Glen ^a   Stenzinger, Albrecht ^b   Wynes, Murry ^d   Hirsch, Fred R ^d   Weichert, Wilko ^b   Heasley, Lynn ^d   Buettner, Reinhard ^c   Perner, Sven ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Colorectal cancer; Fibroblast growth factor receptor 1; NVP BGJ398

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MESSENGER RNA; NVP BGJ 398; UNCLASSIFIED DRUG; 3 (2,6 DICHLORO 3,5 DIMETHOXYPHENYL) 1 [6 [[4 (4 ETHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL] 1 METHYLUREA; PROTEIN;

AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; NUCLEIC ACID AMPLIFICATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CLINICAL ASSESSMENT; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN CELL; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; TISSUE SECTION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, MESSENGER;

EID: 84885509318     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000355018     Document Type: Article

References (24)

1. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
2. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, et al: Inhibitorsensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6:e20351.
3. Liang G, Liu Z, Wu J, Cai Y, Li X: Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012; 33: 531-541.
4. Powers CJ, McLeskey SW, Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-197.
5. Wesche J, Haglund K, Haugsten EM: Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213.
6. Nakao K, Mehta KR, Fridlyand J, Moore DH, Jain AN, Lafuente A, Wiencke JW, Terdiman JP, Waldman FM: High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 2004; 25: 1345-1357. (Pubitemid 39162701)
7. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al: The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
8. Knights V, Cook SJ: De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010; 125: 105-117.
9. Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H, et al: TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol 2009; 217: 65-72.
10. Goeke F, Franzen A, Menon R, Goltz D, Kirsten R, Boehm D, Vogel W, Goeke A, Scheble V, Ellinger J, et al: Rationale for treatment of metastatic squamous cell carcinoma of the lung using FGFR inhibitors. Chest 2012; 142: 1020-1026.
11. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, et al: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012; 44: 1104-1110.
12. Ney JT, Froehner S, Roesler A, Buettner R, Merkelbach-Bruse S: High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin- embedded tissues. Arch Pathol Lab Med 2012; 136: 983-992.
13. Lankat-Buttgereit B, Muller S, Schmidt H, Parhofer KG, Gress TM, Goke R: Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line. Biol Cell 2008; 100: 703-715.
14. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113. (Pubitemid 350134889)
15. Lao VV, Grady WM: Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 686-700.
16. Goel A, Boland CR: Epigenetics of colorectal cancer. Gastroenterology 2012; 143: 1442-1460.
17. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia- Foncillas J: Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 2009; 125: 2737-2743.
18. Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, et al: FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2012; 2: 1118-1133.
19. Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J: Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 2012; 13: 12153-12168.
20. Stachowiak MK, Fang X, Myers JM, Dunham SM, Berezney R, Maher PA, Stachowiak EK: Integrative nuclear FGFR1 signaling (INFS) as a part of a universal feed-forward-andgate signaling module that controls cell growth and differentiation. J Cell Biochem 2003; 90: 662-691. (Pubitemid 37392460)
21. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H, et al: Discovery of 3-(2,6-dichloro-3,5- dimethoxy-phen yl)-1- [6-(4-ethyl-piperazin-1-yl)phenylamino-pyrimidin- 4-yl]-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54: 7066-7083.
22. Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, Reiche JA, Hermeking H, Rizzani A, Bruns CJ, et al: Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 2010; 16: 5529-5538.
23. Peng H, Myers J, Fang X, Stachowiak EK, Maher PA, Martins GG, Popescu G, Berezney R, Stachowiak MK: Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C. J Neurochem 2002; 81: 506-524. (Pubitemid 34809329)
24. Wong A, Lamothe B, Lee A, Schlessinger J, Lax I: FRS2-? attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci USA 2002; 99: 6684-6689. (Pubitemid 34526193)